Brookfield Asset Management Inc. Apellis Pharmaceuticals, Inc. Transaction History

Brookfield Asset Management Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Sep 25, 2023	SELL	$76.68 - $93.31 $4.2 Million - $5.11 Million	-54,726 Reduced 47.12%	61,414 $5.59 Million
Q2 2023 Aug 14, 2023	SELL	$76.68 - $93.31 $4.2 Million - $5.11 Million	-54,726 Reduced 47.12%	61,414 $5.59 Million
Q1 2023 Sep 25, 2023	BUY	$46.59 - $66.96 $2.55 Million - $3.66 Million	54,726 Added 89.11%	116,140 $7.66 Million
Q1 2023 May 15, 2023	BUY	$46.59 - $66.96 $2.33 Million - $3.34 Million	49,914 Added 75.37%	116,140 $7.66 Million
Q4 2022 Feb 14, 2023	BUY	$43.24 - $61.04 $259,267 - $365,995	5,996 Added 9.96%	66,226 $3.42 Million
Q3 2022 Nov 14, 2022	BUY	$44.76 - $69.66 $1.16 Million - $1.8 Million	25,890 Added 75.39%	60,230 $4.11 Million
Q2 2022 Nov 16, 2022	SELL	$35.07 - $59.21 $907,962 - $1.53 Million	-25,890 Reduced 42.99%	34,340 $1.55 Million
Q2 2022 Aug 15, 2022	BUY	$35.07 - $59.21 $682,953 - $1.15 Million	19,474 Added 131.0%	34,340 $1.55 Million
Q1 2022 May 16, 2022	BUY	$35.46 - $54.12 $527,148 - $804,547	14,866 New	14,866 $755,000

308

115M

3.85M

1.09M

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.64B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

Get notified when there are updates to the investment portfolio of Brookfield Asset Management Inc., based on Form 13F filings with the SEC.

Stay updated on Brookfield Asset Management Inc. with notifications on news.